ClinicalTrials.gov record
Not listed Phase 1 Interventional

IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma

ClinicalTrials.gov ID: NCT00003842

Public ClinicalTrials.gov record NCT00003842. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study of a Recombinant Chimeric Protein Composed of Circularly Permuted IL-4 and a Mutated Form of the Pseudomonas Exotoxin Termed IL-4(38-37)-PE38KDEL (IL-4 Toxin) for the Treatment of Recurrent Malignant Astrocytoma

Study identification

NCT ID
NCT00003842
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Barrett Cancer Center
Other
Enrollment
30 participants

Conditions and interventions

Interventions

  • interleukin-4 PE38KDEL cytotoxin Biological
  • isolated perfusion Drug
  • surgical procedure Procedure

Biological · Drug · Procedure

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 1999
Primary completion
Not listed
Completion
Not listed
Last update posted
Dec 17, 2013

Started 1999

United States locations

U.S. sites
10
U.S. states
6
U.S. cities
9
Facility City State ZIP Site status
University of Southern California, Healthcare Consultation Center Los Angeles California 90033
UCSF Cancer Center and Cancer Research Institute San Francisco California 94115-0128
Neuro-Oncology Service San Francisco California 94143-0372
John Wayne Cancer Institute Santa Monica California 90404
Laboratory of Molecular Biology Bethesda Maryland 20892
Food and Drug Administration Rockville Maryland 20857
St. Louis University Health Sciences Center St Louis Missouri 63110-0250
Herbert Irving Comprehensive Cancer Center New York New York 10032
Charlotte Neurosurgical Associates Charlotte North Carolina 28207-1830
Barrett Cancer Center, The University Hospital Cincinnati Ohio 45219

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003842, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 17, 2013 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00003842 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →